BioNTech (NASDAQ:BNTX) Upgraded at Jefferies Financial Group

Jefferies Financial Group upgraded shares of BioNTech (NASDAQ:BNTX) from a hold rating to a buy rating in a report issued on Tuesday morning, Marketbeat reports. Jefferies Financial Group currently has $150.00 price objective on the stock, up from their prior price objective of $96.00.

A number of other equities research analysts have also weighed in on the company. Hsbc Global Res upgraded BioNTech from a hold rating to a strong-buy rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. upgraded shares of BioNTech from an underweight rating to a neutral rating and upped their price target for the company from $91.00 to $125.00 in a research note on Monday. Bank of America lifted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the stock a buy rating in a research note on Monday. HSBC raised BioNTech from a hold rating to a buy rating in a research report on Friday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft raised BioNTech from a hold rating to a buy rating and set a $95.00 price target for the company in a research report on Wednesday, August 7th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus price target of $124.54.

BioNTech Trading Down 2.7 %

NASDAQ BNTX opened at $112.51 on Tuesday. The firm has a market cap of $26.75 billion, a PE ratio of 225.02 and a beta of 0.23. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $89.71 and a 200 day moving average price of $90.31.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter in the prior year, the company posted ($0.86) EPS. The business’s revenue for the quarter was down 23.3% on a year-over-year basis. As a group, sell-side analysts forecast that BioNTech will post -2.8 EPS for the current fiscal year.

Institutional Trading of BioNTech

Hedge funds have recently added to or reduced their stakes in the company. Primecap Management Co. CA raised its position in shares of BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after acquiring an additional 131,490 shares during the period. Harding Loevner LP purchased a new position in shares of BioNTech in the 4th quarter valued at about $410,984,000. Capital World Investors raised its holdings in BioNTech by 0.5% in the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock worth $87,002,000 after purchasing an additional 4,369 shares during the period. Deerfield Management Company L.P. Series C boosted its position in BioNTech by 4.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after purchasing an additional 24,426 shares in the last quarter. Finally, Candriam S.C.A. grew its holdings in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.